Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...
PharmiWeb9 小时
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...
The Pharma Letter10 小时
Sarclisa gains new approval in Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...
PharmiWeb5 小时
Strong real-world efficacy and safety data with Pepaxti published in the European Journal ...
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...
Sanofi: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...